The 2026 ACC/AHA Multisociety Dyslipidemia Guideline and PREVENT-ASCVD Risk Assessment: A Contemporary Clinical Review

Abstract

Purpose: Dyslipidemia remains a central causal and modifiable driver of atherosclerotic cardiovascular disease (ASCVD). The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia represents the most consequential United States lipid management update since the 2018 cholesterol guideline. It restores explicit LDL-C and non-HDL-C treatment goals, expands lifetime lipid assessment, incorporates lipoprotein(a) and apolipoprotein B into risk personalization, and replaces the Pooled Cohort Equations with the American Heart Association PREVENT-ASCVD equations for primary prevention risk assessment. This clinical review summarizes the major changes in the 2026 dyslipidemia guideline and proposes a practical framework for clinical implementation. 

Key Highlights: The guideline transitions lipid management from a threshold-based approach toward a more structured and individualized strategy. In adults aged 30 to 79 years without known ASCVD or subclinical atherosclerosis and LDL-C levels of 70 to 189 mg/dL, PREVENT-ASCVD is recommended for 10-year risk estimation, while 30-year risk assessment is emphasized in adults aged 30 to 59 years. Lipid-lowering therapy is recommended at lower estimated risk thresholds than in prior Pooled Cohort Equation-based strategies. Key updates include LDL-C goals of < 100 mg/dL for low, borderline, or intermediate-risk primary prevention patients and < 70 mg/dL for high-risk individuals. Secondary prevention targets include LDL-C < 55 mg/dL for very-high-risk ASCVD and < 70 mg/dL for ASCVD not classified as very high risk. Additional recommendations include universal adult lipoprotein(a) measurement at least once, selective apolipoprotein B assessment for residual risk evaluation, and earlier incorporation of evidence-based non-statin therapies when statins alone fail to achieve lipid goals. 

Conclusion: The 2026 dyslipidemia guideline establishes a more aggressive, risk-based, and goal-directed prevention paradigm emphasizing earlier intervention, personalized risk assessment, and timely treatment intensification to reduce residual cardiovascular risk.